Study Disputes Claims on Breast Cancer Drug
From Times Wire Reports
Final results from a large study comparing two drugs for preventing breast cancer challenge the government’s claim that raloxifene is safer than the old standby, tamoxifen.
In April, the National Cancer Institute, which paid for the $88-million study, said users of raloxifene had fewer uterine cancers and blood clots.
But study results released in Atlanta showed that the number of uterine cancer cases differed so little that they could have happened by chance. And so few blood clots occurred that some doctors didn’t believe the result proved raloxifene was better.
